krn-7000 has been researched along with Liver-Diseases* in 3 studies
1 review(s) available for krn-7000 and Liver-Diseases
Article | Year |
---|---|
Role of NKT cells in the digestive system. I. Invariant NKT cells and liver diseases: is there strength in numbers?
Information regarding the functional role of the innate immune T cell, invariant natural killer T (iNKT) cells, in the pathophysiology of liver diseases continues to emerge. Results from animal studies suggest that iNKT cells can have divergent roles by specifically promoting the development of proinflammatory or anti-inflammatory responses in liver diseases. In this themes article, I discuss the critical evidence from animal models that demonstrate a vital role for iNKT cells in the pathophysiology of liver diseases with emphasis on viral, autoimmune, and toxin-induced liver diseases. Furthermore, I discuss the controversial issues (including iNKT cell apoptosis) that typify some of these studies. Finally, I highlight areas that require additional investigation. Topics: Animals; Apoptosis; Chemical and Drug Induced Liver Injury; Galactosylceramides; Killer Cells, Natural; Liver; Liver Diseases | 2007 |
2 other study(ies) available for krn-7000 and Liver-Diseases
Article | Year |
---|---|
A critical role for IFN regulatory factor 1 in NKT cell-mediated liver injury induced by alpha-galactosylceramide.
NKT cells are remarkably abundant in mouse liver. Compelling experimental evidence has suggested that NKT cells are involved in the pathogenesis of many liver diseases. Activation of NKT cells with alpha-galactosylceramide (alpha-GalCer) causes liver injury through mechanisms that are not well understood. We undertook studies to characterize the key pathways involved in alpha-GalCer-induced liver injury. We found that expression of the transcription factor IFN regulatory factor 1 (IRF-1) in mouse liver was dramatically upregulated by alpha-GalCer treatment. Neutralization of either TNF-alpha or IFN-gamma inhibited alpha-GalCer-mediated IRF-1 upregulation. alpha-GalCer-induced liver injury was significantly suppressed in IRF-1 knockout mice or in wild-type C56BL/6 mice that received a microRNA specifically targeting IRF-1. In contrast, overexpression of IRF-1 greatly potentiated alpha-GalCer-induced liver injury. alpha-GalCer injection also induced a marked increase in hepatic inducible NO synthase expression in C56BL/6 mice, but not in IRF-1 knockout mice. Inducible NO synthase knockout mice exhibited significantly reduced liver injury following alpha-GalCer treatment. Finally, we demonstrated that both NKT cells and hepatocytes expressed IRF-1 in response to alpha-GalCer. However, it appeared that the hepatocyte-derived IRF-1 was mainly responsible for alpha-GalCer-induced liver injury, based on the observation that inhibition of IRF-1 by RNA interference did not affect alpha-GalCer-induced NKT cell activation. Our findings revealed a novel mechanism of NKT cell-mediated liver injury in mice, which has implications in the development of human liver diseases. Topics: Animals; Blotting, Western; Flow Cytometry; Galactosylceramides; Gene Expression; Gene Knockout Techniques; Hepatocytes; Interferon Regulatory Factor-1; Interferon-gamma; Liver; Liver Diseases; Lymphocyte Activation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Natural Killer T-Cells; Nitric Oxide Synthase Type II; Reverse Transcriptase Polymerase Chain Reaction; Tumor Necrosis Factor-alpha | 2010 |
A murine model of NKT cell-mediated liver injury induced by alpha-galactosylceramide/d-galactosamine.
Natural killer-T (NKT) cells are rich in the liver. However, their involvement in liver injury is not fully understood. We developed here a new murine model of NKT-cell-activation-associated liver injury, and investigated a role of tumor necrosis factor alpha (TNF-alpha) and Fas in pathogenesis. We injected intraperitoneally alpha-galactosylceramide (alpha-GalCer), an NKT-cell stimulant, into D-galactosamine (GalN)-sensitized mice. Survival rate, pathological changes of the liver, and plasma concentrations of cytokines were studied. Alpha-GalCer/GalN administration gave a lethal effect within 7 h, making pathological changes such as massive parenchymal hemorrhage, hepatocyte apoptosis, sinusoidal endothelial cell injury, and close apposition of lymphocytes to apoptotic hepatocytes. Anti-NK1.1 mAb-pretreated mice and Valpha14NKT knock out (KO) mice did not develop liver injury. Tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) were elevated at 4 h in the plasma. These cytokines were produced by hepatic lymphocytes as demonstrated by in vitro stimulation with alpha-GalCer. The lethal effect was suppressed in TNF-alpha KO mice, TNF receptor-1 KO mice, and lpr/lpr (Fas deficient) mice, whereas it was not in IFN-gamma KO mice. These results indicate that the present liver injury is characterized by parenchymal hemorrhage and hepatocyte apoptosis, and mediated by TNF-alpha secretion and direct cytotoxicity of alpha-GalCer-activated NKT cells. Topics: Animals; Apoptosis; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Galactosamine; Galactosylceramides; In Situ Nick-End Labeling; Interferon-gamma; Killer Cells, Natural; Liver; Liver Diseases; Mice; Mice, Knockout; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; Tumor Necrosis Factor-alpha | 2005 |